РЕЖИМЫ НЕТРАДИЦИОННОГО ФРАКЦИОНИРОВАНИЯ В ЛУЧЕВОЙ ТЕРАПИИ РАКА ГОЛОВЫ И ШЕИ



DOI: http://dx.doi.org/10.25298/2221-8785-2019-17-4-368-376


Л. Б. Пархоменко (L. B. Parkhomenko)

Аннотация


Цель обзора – анализ и обобщение литературных данных о роли нетрадиционного фракционирования дозы излучения при лучевом лечении рака органов головы и шеи. Проанализировано 46 англоязычных источников с описанием радиобиологически обоснованных режимов нетрадиционного фракционирования и подтверждением их эффективности по сравнению с конвенциональной лучевой терапией в клинических исследованиях.
Результаты приведенных исследований свидетельствуют о наибольшей пользе при применении гиперфракционирования и умеренно ускоренного фракционирования дозы излучения у пациентов с плоскоклеточным раком органов головы и шеи.

Ключевые слова


рак органов головы и шеи, лучевая терапия, гиперфракционирование, ускоренное фракционирование

Полный текст:

Литература


An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squa-mous cell head and neck cancer / D. J. Adelstein [et al.] // J. Clin. Oncol. – 2003. –Vol. 21, № 1. – P. 92-98.

Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 2003;21(1):92-98. doi: 10.1200/JCO.2003.01.008.

Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy / P. Huguenin [et al.] // J. Clin. Oncol. – 2004. – Vol. 22, № 23. – P. 4665-4673.

Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, Pestalozzi B, Schmid S, Thoni A, Ozsahin M, Bernier J, Topfer M, Kann R, Meier UR, Thum P, Bieri S, Notter M, Lombriser N, Glanzmann C. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J. Clin. Oncol. 2004;22(23):4665-4673. doi: 10.1200/JCO.2004.12.193.

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer / A. A. Forastiere [et al.] // N. Engl. J. Med. – 2003. – Vol. 349, № 22. – P. 2091-2098.

Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 2003;349(22):2091-2098. doi: 10.1056/NEJMoa031317.

Long-term results of RTOG 91-11: A comparison of three nonsurgical treat-ment strategies to preserve the larynx in patients with locally advanced larynx cancer / A. A. Forastiere [et al.] // J. Clin. Oncol. – 2013. – Vol. 31, № 7. – P. 845-852.

Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-term results of RTOG 91-11: A comparison of three nonsurgical treat-ment strategies to preserve the larynx in patients with locally advanced larynx cancer. J. Clin. Oncol. 2013;31(7):845-852. doi: 10.1200/JCO.2012.43.6097.

Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Col-laborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer / J. P. Pignon [et al.] // Lancet. – 2000. – Vol. 355, № 9208. – P. 949-955.

Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locore-gional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949-955.

Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACHNC): An Update on 93 Randomised Trials and 17,346 Patients / J. P. Pignon [et al.] // Radiother. Oncol. – 2009. – Vol. 92, № 1. – P. 4-14.

Pignon JP, Maitre A, Maillard E, Bourhis J. Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACHNC): An Update on 93 Randomised Trials and 17,346 Patients. Radiother. Oncol. 2009;92(1):4-14. doi: 10.1016/j.radonc.2009.04.014.

Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial / J. H. Lorch [et al.] // Lancet Oncol. – 2011. – Vol. 12, № 2. – P. 153-159.

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011;12(2):153-159. doi: 10.1016/S1470-2045(10)70279-5.

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer / J. B. Vermorken [et al.] // N. Engl. J. Med. – 2007. – Vol. 357, № 17. – P. 1695-1704.

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL. Cisplatin, fluorourcil, and docetaxel in unresectable head and neck cancer. N. Engl. I. J. Med. 2007;357(17):1695-1704. doi: 10.1056/NEJMoa071028.

Radiotherapy plus Cetuximab for Squamous-cell carcinoma of the Head and Neck / J. A. Bonner [et al.] // N. Engl. J. Med. – 2006. – Vol. 354, № 6. – P. 567-578.

Bonner JA, Harari PM, J. Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006;354(6):567-578. doi: 10.1056/NEJMoa053422.

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial / J. Bourhis [et al.] // Lancet Oncol. – 2012. – Vol. 13, № 2. – P. 145-153.

Bourhis J, Sire C, Graff P, Gregoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial. Lancet Oncol. 2012;13(2):145-153. doi: 10.1016/S1470-2045(11)70346-1.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival / J. A. Bonner [et al.] // Lancet Oncol. – 2010. – Vol. 11, № 1. – P. 21-28.

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radio-therapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-28. doi: 10.1016/S1470-2045(09)70311-0.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival / J. A. Bonner [et al.] // Lancet Oncol. – 2010. – Vol. 11, iss. 1. – P. 21-28. – doi: 10.1016/S1470-2045(09)70311-0.

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radio-therapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-28. doi: 10.1016/S1470-2045(09)70311-0.

Cetuximab and radiotherapy in laryngeal preservation for cancers of the larynx and hypopharynx: a secondary analysis of a randomized clinical trial / J. Bonner [et al.] // JAMA Otolaryngol. Head Neck Surg. – 2016. – Vol. 142, № 9. – P. 842-849.

Bonner J, Giralt J, Harari P, Spencer S, Schulten J, Hossain A, Chang SC, Chin S, Baselga J. Cetuximab and radiotherapy in laryngeal preservation for cancers of the larynx and hypopharynx: a secondary analysis of a randomized clinical trial. JAMA Otolaryngol. Head Neck Surg. 2016;142(9):842-849. doi: 10.1001/jamaoto.2016.1228.

When is chemotherapy in head and neck squamous cell carcinoma not indicated? / M. Haigentz [et al.] // Eur. Arch. Otorhinolaryngol. – 2015. – Vol. 272, iss. 4. – P.781-787.

Haigentz M, Vermorken JB, Forastiere AA, Corry J, Beitler JJ, Strojan P, Hartl DM, Rodrigo JP, Bradford CR, Rinaldo A, Takes RP, Mendenhall WM, Shaha AR, Wolf GT, Ferlito A. When is chemotherapy in head and neck squamous cell carcinoma not indicated? Eur. Arch. Otorhinolaryngol. 2015;272(4):781-787. doi: 10.1007/s00405-014-2894-9.

Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial / S. M. Magrini [et al.] // J. Clin. Oncol. – 2016. – Vol. 34, № 5. – P. 427-435.

Magrini SM, Buglione M, Corvo R, Pirtoli L, Paiar F, Ponticelli P, Petrucci A, Bacigalupo A, Crociani M, Lastrucci L, Vecchio S, Bonomo P, Pasinetti N, Triggiani L, Cavagnini R, Costa L, Tonoli S, Maddalo M, Grisanti S. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J. Clin. Oncol. 2016;34(5):427-435. doi: 10.1200/JCO.2015.63.1671.

Randomized phase III trial of concurrent accelerated radiation plus cis-platin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522 / K. K. Ang [et al.] // J. Clin. Oncol. – 2014. – Vol. 32, № 27. – P. 2940-2950.

Ang KK, Zhang Q, Rosenthal D, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J. Clin. Oncol. 2014;32(27):2940-2950. doi: 10.1200/JCO.2013.53.5633.

How fast is repopulation of tumor cells during the treatment gap? / R. Tarnawski [et al.] // Int. J. Radiat. Oncol. Biol. Phys. – 2002. – Vol. 54, № 1. – P. 229-236.

Tarnawski R, Fowler J, Skladowski K, Swierniak A, Suwiński R, Maciejewski B, Wygoda A. How fast is repopulation of tumor cells during the treatment gap? Int. J. Radiat. Oncol. Biol. Phys. 2002;54(1):229-236.

Peters, L. J. Applying radiobiological principles to combined modality treatment of head and neck cancer: the time factor / L. J. Peters, H. R. Withers // Int. J. Radiat. Oncol. Biol. Phys. – 1997. – Vol. 39, № 4. – Р. 831-836.

Peters LJ, Withers HR. Applying radiobiological principles to combined modality treatment of head and neck cancer: the time factor. Int. J. Radiat. On-col. Biol. Phys. 1997;39(4):831-836. doi: 10.1016/S0360-3016(97)00466-5.

Chapman, J. D. Can the two mechanisms of tumor cell killing by radia-tion be exploited for therapeutic gain? / J. D. Chapman // J. Radiat. Res. – 2014. – Vol. 55, № 1. – Р. 2-9.

Chapman JD. Can the two mechanisms of tumor cell killing by radiation be exploited for therapeutic gain? J. Radiat. Res. 2014;55(1):2-9. doi: 10.1093/jrr/rrt111.

Withers, T. R. The hazard of accelerated tumor clonogen repopulation during radiotherapy / T. R. Withers, J. M. Taylor, B. Maciejtwski // Acta Oncol. – 1988. – Vol. 27, iss. 2. – P. 131-146.

Withers TR, Taylor JM, Maciejtwski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27(2):131-146. doi: 10.3109/02841868809090333.

A randomized multicentre trial of CHART versus conventional radio-therapy in head and neck cancer / S. Dische [et al.] // Radiother. Oncol. – 1997. – Vol. 44, № 2. – Р. 123-136.

Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother. Oncol. 1997;44(2):123-136. doi: 10.1016/S0167-8140(97)00094-7.

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial / J. Overgaard [et al.] // Lancet. – 2003. – Vol. 362, № 9388. – Р. 933-940.

Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362(9388):933-940. doi: 10.1016/s0140-6736(03)14361-9.

Harrington, K. M. Molecular biology for the radiation oncologist: the 5 Rs of radiobiology meet the hallmarks of cancer / K. M. Harrington, P. Jankowsa, M. Hingorani // Clin. Oncol. – 2007. – Vol. 19. – Р. 561-571.

Harrington K, Jankowsa P, Hingorani M. Molecular biology for the radiation oncologist: the 5 Rs of radiobiology meet the hallmarks of cancer. Clin. Oncol. 2007;19:561-571. doi:10.1016/j.clon.2007.04.009.

Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis / B. O’Sullivan // Clin. Oncol. – 2013. – Vol. 31, № 5. – P. 543-550.

O’Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, Dawson LA, Hope A, Cho J, Irish J, Gilbert R, Gullane P, Hui A, Liu FF, Chen E, Xu W. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J. Clin. Oncol. 2013;31(5):543-550. doi: 10.1200/JCO.2012.44.0164.

E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx - ECOG-ACRIN Cancer Research Group / S. Marur [et al.] // J. Clin. Oncol. – 2016. – Vol. 35, № 5. – P. 490-497.

Marur S, Li S, Cmelak AJ, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx - ECOG-ACRIN Cancer Research Group. J. Cljn. Oncol. 2017;35(5):490-497. doi: 10.1200/JCO.2016.68.3300.

Reduced-dose radiotherapy for human papillomavirus-associated squa-mous-cell carcinoma of the oropharynx: a single-arm, phase 2 study / A. M. Chen [et al.] // Lancet Oncol. – 2017. – Vol. 18, № 6. – P. 803-811.

Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, Beron P, Wong D, Rosove MH, Rao S, Melanson H, Kim E, Palmer D, Qi L, Kelly K, Steinberg ML, Kupelian PA, Daly ME. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 2017;18(6):803-811. doi: 10.1016/S1470-2045(17)30246-2.

Patient-reported quality-of-life outcomes after de-escalated chemoradia-tion for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial / J. V. Hegde [et al.] // Cancer. – 2018. – Vol. 124, № 3. – P. 521-529.

Hegde JV, Shaverdian N, Daly ME, Felix C,Wong DL, Rosove MH, Garst JH, Wang P‐C, Veruttipong D, Rao S, Fragoso RC, Riess JW, Steinberg ML, Chen AM. Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer. 2018;124(3):521-529. doi: 10.1002/cncr.30954.

Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual / W. M. Lydiatt [et al.] // CA Cancer J. Clin. – 2017. – Vol. 67, № 2. – Р. 122-137.

Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM, Shah JP. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J. Clin. 2017;67(2):122-137. doi: 10.3322/caac.21389.

TNM Classification of Malignant Tumours / ed.: J. D. Brierley, M. K. Gospodarowicz, C. Wittekind. – 8th ed. – Chichester : Wiley-Blackwell, 2017. – 272 р.

Brierley JD, Gospodarowicz MK, Wittekind C, editors. TNM Classification of Malignant Tumours. 8th ed. Chichester: Wiley-Blackwell; 2017. 272 р.

A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcino-mas: first report of RTOG 9003 / K. K. Fu [et al.] // Int. J. Radiat. Oncol. Biol. Phys. – 2000. – Vol. 48, № 1. – Р. 7-16.

Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys. 2000;48(1):7-16.

Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer / J. J. Beitler [et al.] // Int. J. Radiat. Oncol. Biol. Phys. – 2014. – Vol. 89, № 1. – Р. 13-20.

Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, Garden AS, Shenouda G, Harris J, Ang KK. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2014;89(1):13-20. doi: 10.1016/j.ijrobp.2013.12.027.

ICRU Report 62: prescribing, recording, and reporting photon-beam therapy (supplement to ICRU Report 50) / T. Landberg [et al.] // J. ICRU. – 1999. – Vol. os32, iss. 1. – doi: 10.1093/jicru/os32.1.Report62.

Landberg T, Chavaudra J, Dobbs J, Gerard JP, Hanks G, Horiot JC, Johansson KA, Moller T, Purdy J, Suntharalingam N, Svensson H. ICRU Report 62: prescribing, recording, and reporting photon-beam therapy (supplement to ICRU Report 50). J. ICRU. 1999;32(1). doi: 10.1093/jicru/os32.1.Report62.

ICRU Report 83: prescribing, recording, and reporting photon-beam in-tensity-modulated radiation therapy (IMRT) / International Commission on Radiation Units and Measurements // J. ICRU. – 2010. – Vol. 10, iss, 1. – doi: 10.1093/jicru/10.1.Report83.

International Commission on Radiation Units and Measurements. ICRU Report 83: prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). J. ICRU. 2010;10(1). doi: 10.1093/jicru/10.1.Report83.

Patterns of disease recurrence following treatment of oropharyngeal can-cer with intensity modulated radiation therapy / A. S. Garden [et al.] // Int. J. Ra-diat. Oncol. Biol. Phys. – 2013. – Vol. 85, № 4. – Р. 941-947.

Garden AS, Dong L, Morrison WH, Stugis EM, Glisson BS, Frank SJ, Beadle BM, Gunn GB, Schwartz DL, Kies MS, Weber RS, Ang KK, Rosenthal DI. Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2013;85(4):941-947. doi: 10.1016/j.ijrobp.2012.08.004.

Defining risk levels in locally advanced head and neck cancers: a com-parative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) / J. Bernier [et al.] // Head Neck. – 2005. – Vol. 27, № 10. – Р. 843-850.

Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefebvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843-850. doi: 10.1002/hed.20279.

Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck / J. S. Cooper [et al.] // Int. J. Radiat. Oncol. Biol. Phys. – 2012. – Vol. 84, № 5. – P. 1198-1205.

Cooper JS, Zhang Q, Pajak TF, Forastiere АА, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman М, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang КК. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 2012;30;84(5):1198-1205. doi: 10.1016/j.ijrobp.2012.05.008.

Chemotherapy added to locoregional treatment for head and neck squa-mous-cell carcinoma: three meta-analyses of updated individual data / J. P. Pignon [et al.] // Lancet. – 2000. – Vol. 355, № 9208. – Р. 949-955.

Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355(9208):949-955.

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy / J. C. Horiot [et al.] // Radiother. Oncol. – 1992. – Vol. 25, № 4. – P. 231-241.

Horiot JC, Le Fur R, N’Guven T, Chenal C, Schraub S, Alfonsi S, Gardani G, van den Bogaert W, Danczak S, Bolla M. Hyperfractionation versus con-ventional fractionation in oropharyngeal carcinoma: final analysis of a rando-mized trial of the EORTC cooperative group of radiotherapy. Radiother. Oncol. 1992;25(4):231-241.

Randomized Phase I/II trial of two variants of accelerated fractionation radiotherapy regimens for advanced head and neck cancer: Results of RTOG 88-09 / K. K. Fu [et al.] // Int. J. Radiat. Oncol. Biol. Phys. – 1995. – Vol. 32, № 3. – Р. 589-598.

Fu KK, Clery M, Ang KK, Byhardt RW, Maor MH, Beitler JJ. Randomized Phase I/II trial of two variants of accelerated fractionation radiotherapy regimens for advanced head and neck cancer: Results of RTOG 88-09. Int. J. Radiat. Oncol. Biol. Phys. 1995;32(3):589-597. doi: 10.1016/0360-3016(95)00078-D.

Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial / J. Overgaard [et al.] // Lancet Oncol. – 2010. – Vol. 11, № 6. – Р. 553-560.

Overgaard J, Mohanti BK, Begum N, Ali R, Agarwal JP, Kuddu M, Bhasker S, Tatsuzaki H, Grau C. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol. 2010;11(6):553-560. doi: 10.1016/S1470-2045(10)70072-3.

The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma / N. M. Lyhne [et al.] // Radiother. Oncol. – 2015. – Vol. 117, № 1. – Р. 91-98.

Lyhne NM, Primdahl H, Kristensen CA, Andersen E, Johansen J, Andersen LJ, Evensen J, Mortensen HR, Overgaard J. The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma. Radiother. Oncol. 2015;117(1):91-98. doi: 10.1016/j.radonc.2015.07.004.

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis / J. Bourhis [et al.] // Lancet. – 2006. – Vol. 368, № 9538. – Р. 843-854.

Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maitre A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368(9538):843-854. doi: 10.1016/S0140-6736(06)69121-6.

A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally ad-vanced squamous cell carcinoma of the head and neck / W. Budach [et al.] // BMC Cancer. – 2006. – Vol. 6. – Р. 28-33.

Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hy-perfractionated and accelerated radiotherapy and combined chemotherapy and ra-diotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006;6:28-33. doi: 10.1186/1471-2407-6-28.

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial / J. Bourhis [et al.] // Lancet Oncol. – 2012. – Vol. 13, № 2. – Р. 145-153.

Bourhis J, Sire C, Graff P, Gregoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Auperin A. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial. Lancet Oncol. 2012;13(2):145-153. doi: 10.1016/S1470-2045(11)70346-1.

Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis / B. Lacas [et al.] // Lancet Oncol. – 2017. – Vol. 18, № 9. – P. 1221-1237.

Lacas B, Bourhis J, Overgaard J, Zhang Q, Gregoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwinski R, Poulsen M, O'Sullivan B, Corvo R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Beadle B, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MK, Auperin A, van Herpen C. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated me-ta-analysis. Lancet Oncol. 2017;18(9):1221-1237. doi: 10.1016/S1470-2045(17)30458-8.

NCCN Guidelines: Head and Neck Cancers. Version 1. 2019. [Electronic resource] // National Comprehensive Cancer Network. – Mode of access: https://www.nccn.org/professionals/physician_gls/default.aspx. – Date of access: 12.07.2019.

NCCN Guidelines: Head and Neck Cancers. Version 1. 2019 [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.


Ссылки

  • На текущий момент ссылки отсутствуют.